Key result
In permeabilized human myocardium, 50 µM para-Nitroblebbistatin reduced isometric force and maximum power by approximately 50% without altering maximum shortening velocity or the rate of force development.
p-value: p=<0.05
para-Nitroblebbistatin reduces the myosin duty ratio and isometric force without altering shortening velocity or relaxation, suggesting a potential mechanism for treating hyper-contractile states like hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
May inform myosin-targeted approaches in hypertrophic cardiomyopathy; hypothesis-generating without clinical translation data.
Tang et al. (2017) studied End-stage heart failure (n=4). para-Nitroblebbistatin vs. Vehicle control (DMSO) was evaluated on Isometric force and maximum power (p=<0.05). In permeabilized human myocardium, 50 µM para-Nitroblebbistatin reduced isometric force and maximum power by approximately 50% without altering maximum shortening velocity or the rate of force development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: